Full Text Journal Articles by
Author Pinar Iyidogan


Find full text journal articles

Plasmonic Sensor Could Enable Label-Free DNA Sequencing.

Arif E Cetin, Pinar Iyidogan, Yuki Hayashi, Mark Wallen, Kandaswamy Vijayan, Eugene Tu, Michael Nguyen, Arnold Oliphant,

We demonstrated a proof-of-principle concept of a label-free platform that enables nucleic acid sequencing by binding methodology. The system utilizes gold surfaces having high fidelity plasmonic nanohole arrays which are very sensitive to minute changes of local refractive indices. Our novel surface chemistry approach ensures accurate identification of correct bases ... Read more >>

ACS Sens (ACS sensors)
[2018, 3(3):561-568]

Cited: 2 times

View full text PDF listing >>

Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor.

Casey G Langdon, James T Platt, Robert E Means, Pinar Iyidogan, Ramanaiah Mamillapalli, Michael Klein, Matthew A Held, Jong Woo Lee, Ja Seok Koo, Christos Hatzis, Howard S Hochster, David F Stern,

Pancreatic adenocarcinoma (PDAC) is the fourth most common cause of cancer-related death in the United States. PDAC is difficult to manage effectively, with a five-year survival rate of only 5%. PDAC is largely driven by activating KRAS mutations, and as such, cannot be directly targeted with therapeutic agents that affect ... Read more >>

Mol. Cancer Ther. (Molecular cancer therapeutics)
[2017, 16(6):1041-1053]

Cited: 4 times

View full text PDF listing >>


SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells.

Casey G Langdon, Norbert Wiedemann, Matthew A Held, Ramanaiah Mamillapalli, Pinar Iyidogan, Nicholas Theodosakis, James T Platt, Frederic Levy, Gregoire Vuagniaux, Shaomeng Wang, Marcus W Bosenberg, David F Stern,

Targeting anti-apoptotic proteins can sensitize tumor cells to conventional chemotherapies or other targeted agents. Antagonizing the Inhibitor of Apoptosis Proteins (IAPs) with mimetics of the pro-apoptotic protein SMAC is one such approach. We used sensitization compound screening to uncover possible agents with the potential to further sensitize lung adenocarcinoma cells ... Read more >>

Oncotarget (Oncotarget)
[2015, 6(35):37410-37425]

Cited: 9 times

View full text PDF listing >>

The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors.

Casey G Langdon, Matthew A Held, James T Platt, Katrina Meeth, Pinar Iyidogan, Ramanaiah Mamillapalli, Andrew B Koo, Michael Klein, Zongzhi Liu, Marcus W Bosenberg, David F Stern,

BRAF inhibitors have revolutionized treatment of mutant BRAF metastatic melanomas. However, resistance develops rapidly following BRAF inhibitor treatment. We have found that BRAF-mutant melanoma cell lines are more sensitive than wild-type BRAF cells to the small molecule tyrosine kinase inhibitor dovitinib. Sensitivity is associated with inhibition of a series of ... Read more >>

Pigment Cell Melanoma Res (Pigment cell & melanoma research)
[2015, 28(4):417-430]

Cited: 6 times

View full text PDF listing >>

Recent findings on the mechanisms involved in tenofovir resistance.

Pinar Iyidogan, Karen S Anderson,

Since its approval for clinical use in 2001, tenofovir (TFV) has become one of the most frequently prescribed nucleotide analogues used in combination with other antiretroviral agents against HIV-1 infection. Although reverse transcriptase inhibitors (RTIs) including TFV have been shown to be highly potent with reasonable safety profiles in the ... Read more >>

Antivir. Chem. Chemother. (Antiviral chemistry & chemotherapy)
[2014, 23(6):217-222]

Cited: 0 times

View full text PDF listing >>

Design, Synthesis, and Antiviral Evaluation of Chimeric Inhibitors of HIV Reverse Transcriptase.

Pinar Iyidogan, Todd J Sullivan, Mahendra D Chordia, Kathleen M Frey, Karen S Anderson,

In a continuing study of potent bifunctional anti-HIV agents, we rationally designed a novel chimeric inhibitor utilizing thymidine (THY) and a TMC derivative (a diarylpyrimidine NNRTI) linked via a polymethylene linker (ALK). The nucleoside, 5'-hydrogen-phosphonate (H-phosphonate), and 5'-triphosphate forms of this chimeric inhibitor (THY-ALK-TMC) were synthesized and the antiviral activity ... Read more >>

ACS Med Chem Lett (ACS medicinal chemistry letters)
[2013, 4(12):1183-1188]

Cited: 0 times

View full text PDF listing >>

Bifunctional inhibition of HIV-1 reverse transcriptase: a first step in designing a bifunctional triphosphate.

Dongyuan Piao, Aravind Basavapathruni, Pinar Iyidogan, Guangxiu Dai, Wolfgang Hinz, Adrian S Ray, Eisuke Murakami, Joy Y Feng, Fei You, Ginger E Dutschman, David J Austin, Kathlyn A Parker, Karen S Anderson,

The onset of resistance to approved anti-AIDS drugs by HIV necessitates the search for novel inhibitors of HIV-1 reverse transcriptase (RT). Developing single molecular agents concurrently occupying the nucleoside and nonnucleoside binding sites in RT is an intriguing idea but the proof of concept has so far been elusive. As ... Read more >>

Bioorg. Med. Chem. Lett. (Bioorganic & medicinal chemistry letters)
[2013, 23(5):1511-1518]

Cited: 3 times

View full text PDF listing >>

Understanding the molecular mechanism of sequence dependent tenofovir removal by HIV-1 reverse transcriptase: differences in primer binding site versus polypurine tract.

Pinar Iyidogan, Karen S Anderson,

Tenofovir (TFV) is a nucleotide reverse transcriptase inhibitor (NtRTI) that is often administered as first-line therapy against human immunodeficiency virus type-1 (HIV-1) infection and acts as a chain terminator when incorporated into viral DNA. However, HIV-1 reverse transcriptase (RT) excises TFV in the presence of either ATP or pyrophosphate, which ... Read more >>

Antiviral Res. (Antiviral research)
[2012, 95(2):93-103]

Cited: 7 times

View full text PDF listing >>

Systematic exploration of active site mutations on human deoxycytidine kinase substrate specificity.

Pinar Iyidogan, Stefan Lutz,

Human deoxycytidine kinase (dCK) is responsible for the phosphorylation of a number of clinically important nucleoside analogue prodrugs in addition to its natural substrates, 2'-deoxycytidine, 2'-deoxyguanosine, and 2'-deoxyadenosine. To improve the low catalytic activity and tailor the substrate specificity of dCK, we have constructed libraries of mutant enzymes and tested ... Read more >>

Biochemistry (Biochemistry)
[2008, 47(16):4711-4720]

Cited: 14 times

View full text PDF listing >>


0.95 s